SCHEMBL23414823

SCHEMBL23414823

CSc1ccn2c(=O)cc(C(F)(F)F)nc2c1

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ PKM P14618 1/20 0.38
▸ LMNA P02545 1/20 0.36
▸ GRIN1 Q05586 1/20 0.36
▸ GRIN2A Q12879 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ KDM5B Q9UGL1 1/20 0.35
▸ PTGS2 P35354 1/20 0.35
▸ ALPI P09923 5/20 0.34
▸ ALPL P05186 4/20 0.34
▸ POLB P06746 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23414710 0.85 ALDH1A1 (0.49) ALDH1A1KDM4EMEN1KMT2APKM
SCHEMBL23415012 0.81 ALDH1A1 (0.64) ALDH1A1KDM4EPKMLMNAGRIN1
SCHEMBL23414762 0.79 ALDH1A1 (0.42) ALDH1A1KDM4EMEN1KMT2APKM
SCHEMBL23414575 0.79 USP7 (0.45) ALDH1A1KDM4EMEN1KMT2APKM
SCHEMBL23414795 0.78 ALDH1A1 (0.41) ALDH1A1KDM4EMEN1KMT2APKM
SCHEMBL23414701 0.78 ALDH1A1 (0.41) ALDH1A1KDM4EMEN1KMT2APKM
SCHEMBL23414793 0.78 GRIN1 (0.43) ALDH1A1KDM4EMEN1KMT2APKM
SCHEMBL23414978 0.77 ALPI (0.46) ALDH1A1KDM4EPKMLMNAGRIN1
SCHEMBL23414804 0.77 ALPL (0.45) ALDH1A1KDM4EMEN1KMT2APKM
SCHEMBL23414770 0.77 ALPI (0.43) ALDH1A1KDM4EMEN1KMT2APKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12473289-B2 Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use AMGEN INC. (US) 2025-11-18 — — US disclosed
EP-4065579-A1 HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE Amgen Inc. (US) 2022-10-05 — — EP disclosed
US-20210171529-A1 HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE AMGEN INC. 2021-06-10 — — US disclosed
US-20210171529-A1 HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE AMGEN INC. 2021-06-10 — — US disclosed
WO-2021108404-A1 HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE AMGEN INC. (US) 2021-06-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210171529-A1 HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE SCD5, SCD, FADS2 ALDH1A1 326/4885KDM4E 933/4885MEN1 3962/4885
US-12473289-B2 Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use SCD5, SCD, FADS2 ALDH1A1 326/4885KDM4E 933/4885MEN1 3962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback